More than 100 pharmaceutical companies have been rated, and institutions have paid close attention to the segments of traditional Chinese medicine and offline pharmacies

【Pharmaceutical Network Industry News】Data treasure statistics, from September 2 to September 8, the pharmaceutical and biological industry received intensive attention from institutions, and 103 listed companies received ratings
.

Among the segments, the top institutional attention includes traditional Chinese medicine, offline pharmacies, and medical research and development outsourcing
.

Among them, the number of individual stocks with more than 10 institutional ratings includes Yifeng Pharmacy, Kanglong Huacheng, Ordinary People, and Tongrentang, and the number of institutional rating companies is 13, 12, 11 and 10 respectively
.

Among the 4 individual stocks, Tongrentang belongs to the traditional Chinese medicine industry, Kanglonghua has become the head enterprise of pharmaceutical outsourcing, and Yifeng Pharmacy and the people belong to the offline pharmacy industry
.

According to the semi-annual report of 2022, Yifeng Pharmacy achieved a total operating income of 8.
75 billion yuan in the first half of 2022, an increase of 19.
1% year-on-year; Achieved a net profit attributable to the mother of 576 million yuan, an increase of 14.
2% year-on-year; Earnings per share were RMB0.
8
.

During the reporting period, the company added 1391 stores to 9200 stores by the first half of 2022
.

It is worth mentioning that in the first half of the year, the company's online business achieved a large degree of growth, with the help of supply chain advantages and digital refined operation system, during the reporting period, the company's Internet business achieved operating income of 816 million yuan, an increase of 81.
4%
year-on-year.

In the first half of the year, the people achieved operating income of 8.
991 billion yuan, an increase of 20.
51% year-on-year, of which the retail pharmacy business income was 7.
584 billion yuan, an increase of 19.
6% year-on-year; Attributable net profit was RMB457 million, up 12.
48%
year-on-year.

By the first half of 2022, the people have the majority of stores, and they have built a marketing network
covering 10,009 stores in 20 provinces.

In addition, in the offline pharmacy sector, Yixintang, Dashenlin and Jianzhijia have also received the attention of institutions, and the number of institutional ratings is 9, 7 and 4 respectively
.

According to the semi-annual report of Yixintang, the operating income was 7.
965 billion yuan, an increase of 18.
85% year-on-year, and as of the first half of 2022, the number of stores was 8990
.

It should be noted that in the first half of the year, the retail pharmacy business revenue of Yixintang was 6.
318 billion yuan, an increase of only 5.
11%
year-on-year.

In the first half of the year, the operating income of Da ginseng forest was 9.
721 billion yuan, an increase of 20.
68% year-on-year, of which the retail pharmacy business income was 8.
781 billion yuan, an increase of 18.
78% year-on-year; Attributable net profit was 714 million, up 10.
62%
year-on-year.

In the first half of 2022, the retail pharmacy business of Da ginseng forest accounted for 90.
33%.


It has 8896 stores
.

Jianzhijia achieved operating income of 3.
006 billion yuan, an increase of 26.
34% year-on-year, of which the retail pharmacy business revenue was 2.
653 billion yuan, an increase of 27.
81%; Attributable net profit was 0.
88 billion, down 28.
16%
year-on-year.

It is reported that its pharmaceutical retail, that is, retail pharmacy business accounted for 88.
26%.


The number of existing stores of Jianzhijia is 3283
.

On the news side, in order to ensure the quality and safety of drugs, facilitate the use of drugs by the masses, and improve the design of the drug network sales supervision and management system, etc.
, the State Administration for Market Regulation recently issued the "Measures for the Supervision and Administration of Drug Network Sales", which will be implemented from
December 1, 2022.

The Measures stipulate
the management of drug network sales, the performance of platform responsibilities, supervision and inspection measures and legal responsibilities.

It clarifies the qualifications and requirements of drug trading enterprises engaged in drug network sales, and clarifies in accordance with law that drugs under special management by the state, such as vaccines, blood products, narcotic drugs, psychotropic substances, toxic drugs for medical use, radioactive drugs, and precursor chemicals such as pharmaceuticals, must not be sold
on the Internet.

Founder Securities Research Report believes that the introduction of new regulations on online drug sales, the convergence of online and offline supervision, the upgrading and transformation of new retail formats in pharmacies are developing in the direction of standardization, and the scale effect of the head chain pharmacy is prominent
.

Previously, Southwest Securities said that the concentration of chain pharmacies in China is still continuing to increase, and the space for large chain acquisitions and self-built stores is large, which is the core trend
of chain pharmacies.

The prescription outflow business continues to be laid out, and it is expected that hundreds of billions of yuan will continue to flow to pharmacies
.

Both factors are good for large chain pharmacies
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.